518 related articles for article (PubMed ID: 24012393)
1. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
Cidado J; Park BH
J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):205-16. PubMed ID: 22865098
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Manfredi GI; Dicitore A; Gaudenzi G; Caraglia M; Persani L; Vitale G
Endocrine; 2015 Mar; 48(2):363-70. PubMed ID: 25115638
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K-AKT-mTOR signaling network in cancer.
Khan KH; Yap TA; Yan L; Cunningham D
Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/AKT/mTOR network for treatment of leukemia.
Bertacchini J; Heidari N; Mediani L; Capitani S; Shahjahani M; Ahmadzadeh A; Saki N
Cell Mol Life Sci; 2015 Jun; 72(12):2337-47. PubMed ID: 25712020
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Owonikoko TK; Khuri FR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
[TBL] [Abstract][Full Text] [Related]
9. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
Lauring J; Park BH; Wolff AC
J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
Cho DC
BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
[TBL] [Abstract][Full Text] [Related]
11. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
Sacco A; Roccaro A; Ghobrial IM
Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
[TBL] [Abstract][Full Text] [Related]
12. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
13. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B; Dienstmann R; Tabernero J
Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
[TBL] [Abstract][Full Text] [Related]
15. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
16. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
17. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
LoRusso PM
J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
LoPiccolo J; Blumenthal GM; Bernstein WB; Dennis PA
Drug Resist Updat; 2008; 11(1-2):32-50. PubMed ID: 18166498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
